

## Original Article



# Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Hyunmee Kim <sup>1,\*</sup>, Hyeongsoo Kim <sup>2,\*</sup>, Seong-Kyung Cho <sup>1</sup>, Jin-Bae Kim <sup>3</sup>, Boyoung Joung <sup>1</sup>, MD<sup>2,†</sup>, and Changsoo Kim <sup>1</sup>, MD, PhD<sup>1,†</sup>

<sup>1</sup>Department of Preventive Medicine, Institute of Human Complexity and Systems Science, Yonsei University College of Medicine, Seoul, Korea

<sup>2</sup>Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea

<sup>3</sup>Division of Cardiology, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University, Seoul, Korea

 OPEN ACCESS

Received: Jul 3, 2018

Revised: Sep 7, 2018

Accepted: Oct 23, 2018

## Correspondence to

Changsoo Kim, MD, PhD

Department of Preventive Medicine, Institute of Human Complexity and Systems Science, Yonsei University College of Medicine, 50, Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.  
E-mail: [creman@yuhs.ac](mailto:creman@yuhs.ac)

## Boyoung Joung, MD

Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 50, Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.  
E-mail: [cby6908@yuhs.ac](mailto:cby6908@yuhs.ac)

\*Hyunmee Kim and Hyeongsoo Kim contributed equally to this work.

†Joint senior authors.

Copyright © 2019. The Korean Society of Cardiology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

## ORCID iDs

Hyunmee Kim   
<https://orcid.org/0000-0002-7006-1656>

Hyeongsoo Kim   
<https://orcid.org/0000-0002-5030-952X>

## ABSTRACT

**Background and Objectives:** Rivaroxaban is noninferior to warfarin for preventing stroke or systemic embolism in patients with high-risk atrial fibrillation (AF) and is associated with a lower rate of intracranial hemorrhage (ICH). We assessed the cost-effectiveness of rivaroxaban compared to adjusted-dose warfarin for the prevention of stroke in patients with nonvalvular AF.

**Methods:** We built a Markov model using the Korean Health Insurance Review & Assessment Service database. The base-case analysis assumed a cohort of patients with prevalent AF who were aged 18 years or older without contraindications to anticoagulation.

**Results:** Number of patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc scores 0, 1 and ≥2 were 56 (0.2%), 1,944 (6.3%) and 28,650 (93.5%), respectively. In patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc scores ≥2, the incidence rate of ischemic stroke was 3.11% and 3.76% in warfarin and rivaroxaban groups, respectively. The incidence rates of ICH were 0.42% and 0.15%, and those of gastrointestinal bleeding were 0.32% and 0.15% in warfarin and rivaroxaban, respectively. Patients with AF treated with rivaroxaban lived an average of 11.8 quality-adjusted life years (QALYs) at a lifetime treatment cost of \$20,886. Those receiving warfarin lived an average of 11.4 QALYs and incurred costs of \$17,151. Patients with rivaroxaban gained an additional 0.4 QALYs over a lifetime with an additional cost of \$3,735, resulting in an incremental cost-effectiveness ratio of \$9,707 per QALY.

**Conclusions:** Patients who had been treated with rivaroxaban may be a cost-effective alternative to warfarin for stroke prevention in Korean patients with AF.


**Keywords:** Atrial fibrillation; Rivaroxaban; Warfarin; Cost effectiveness

## INTRODUCTION

Atrial fibrillation (AF) is the most commonly encountered cardiac arrhythmia in the clinical practice,<sup>1,2)</sup> and is associated with a 4- to 5-fold increase in stroke risk.<sup>2)</sup> Stroke prevention is the principal management priority in patients with AF. Vitamin K antagonists (VKAs) have been the maintenance of oral anticoagulant (OAC) treatment for several decades and reduce the relative risk of stroke in patients with AF by 64% and all-cause mortality by 26%,

Seong-Kyung Cho 


<https://orcid.org/0000-0002-8524-2732>

Jin-Bae Kim 

<https://orcid.org/0000-0002-0293-0901>

Boyoung Joung 

<https://orcid.org/0000-0001-9036-7225>

Changsoo Kim 

<https://orcid.org/0000-0002-5940-5649>

#### Funding

This study was supported by a research grant from the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology, and grants from the Korean Healthcare Technology R&D project funded by the Ministry of Health & Welfare (HC15C1200).

#### Conflict of Interest

The authors have no financial conflicts of interest.

#### Author Contributions

Data curation: Kim JB; Formal analysis: Cho SK; Writing - original draft: Kim H, Kim H; Writing - review & editing: Joung B, Kim C.

compared to control.<sup>3)</sup> However, VKAs have many limitations including narrow therapeutic window, variability in dose response, slow onset and offset of action, and food and drug interactions.<sup>4)</sup>

The non-VKA oral anticoagulants (NOACs) have all been proven at least as effective and safe as warfarin in large randomized controlled trials,<sup>5-8)</sup> with a lower incidence of intracranial hemorrhage (ICH). Indeed, NOACs also have advantages compared with warfarin, such as fewer drug–drug and food–drug interactions and no requirement for routine coagulation monitoring.<sup>9)</sup> Current guidelines recommend preferential use of NOAC in patients with nonvalvular AF and risk of thromboembolic events.<sup>10)11)</sup> Nevertheless, the use of NOAC has been limited due to both economical and medical reasons.

In patients with AF, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism. There was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivaroxaban group.<sup>6)</sup> Cost-effectiveness of NOAC was well demonstrated in western countries. However, it has not been well assessed in Asian countries. The aim of our study was to evaluate the costs, cost-effectiveness, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) of rivaroxaban compared to adjusted-dose warfarin for the prevention of stroke in Korean patients with AF.

## METHODS

This study is based on the national health claims database established by the Health Insurance Review & Assessment Service (HIRA) of Republic of Korea.<sup>12)13)</sup> The National Health Insurance Service (NHIS) is the single insurer controlled by the Korean government, and the majority (97.1%) of Korean population are mandatory subscribers, with the remaining 3% of the population being medical aid subjects. HIRA database contains the information of medical aid subjects, therefore it is based on the entire Korean population.<sup>12)13)</sup> The sociodemographic information of patients, their use of inpatient and outpatient services, pharmacy dispensing claims, and mortality data are provide. Every subject in the HIRA database was linked by the Korean social security numbers. This study was approved by the Institutional Review Board of Yonsei University Health System (4-2016-0179) and informed consent was waived.

### Study population

In the Korean NHIS data, 109,125 patients with prevalent AF who were aged 18 years or older were identified during the period from January 1, 2012 to December 31, 2014. After the diagnosis of AF, warfarin and rivaroxaban were used to confirm the prescription, and the number of all drugs used in the analysis was calculated. It was prescribed for 20,431 patients with warfarin, and 713 patients with rivaroxaban. The following were exclusion criteria: 1) those with valvular AF such as moderate to severe mitral valve stenosis and prosthetic valve disease (International Classification of Disease [ICD]-I050, I052, I342), and 2) those who ever received treatment with NOAC before enrollment. Finally, this study included 19,895 patients who had taken warfarin and 709 patient who had taken rivaroxaban.

AF was diagnosed using the International Classification of Disease 10th Revision (ICD-10) codes, I48 (AF and atrial flutter), I48.0 (AF), and I48.1 (atrial flutter). Moreover, patients were

defined as AF only when it was a discharge diagnosis or confirmed more than twice in the outpatient department to ensure diagnostic accuracy. The AF diagnosis has previously been validated in the NHIS database with a positive predictive value of 94.1%.<sup>1)14)15)</sup>

### Decision tree model

The cost-effectiveness of rivaroxaban (at a daily dose of 20 mg) compared to adjusted-dose warfarin in patients with AF was evaluated using a Markov chain Monte Carlo model. Rivaroxaban was reduced to a daily dose of 15 mg in patients with creatinine clearance from 15 to 50 mL/min.<sup>16)</sup> The base-case analysis assumed a cohort of patients with AF who were aged 18 years or older regardless of congestive heart failure, hypertension, age  $\geq 75$  (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65 to 74, female (CHA<sub>2</sub>DS<sub>2</sub>-VAsC) score (CVS).

The CHA<sub>2</sub>DS<sub>2</sub>-VAsC score was calculated using the medical history of the past year for AF diagnosis. The CHA<sub>2</sub>DS<sub>2</sub>-VAsC scores of 0, 1 and 2 or more were classified as low-, intermediate- and high-risk group, respectively.<sup>17)</sup>

Adherence rates of therapy were assumed to be similar across all treatments, and the efficacy was assumed to remain constant over time for rivaroxaban and warfarin. Patient movement between health states was modeled using 1-month cycles for 20 years or until death. The mean age of the patients was 66.5 years for men and 71.8 years for women in analysis, and twenty cycles were repeated to determine the transition probability to the final health state, considering that the average life expectation was 77.3 years for men and 84 years for women.<sup>18)</sup>


Baseline comorbidities and outcomes were defined using the medical claims and prescription medication. In order to ensure diagnostic accuracy, the patients were considered to have comorbidities when the condition was a discharge diagnosis or was confirmed at least twice in an outpatient setting, which was similar to previous studies with NHIS (**Supplementary Table 1**).<sup>2)12)19)</sup> The base case included the following health states: healthy, ischemic stroke, ICH, myocardial infarction (MI), and death (**Figure 1**). We classified all events into fatal and non-fatal. Events related with death were defined as fatal events. Non-fatal ischemic stroke included stroke with major (moderated to severe neurologic residua), minor (neurologic residua), or reversible ischemic neurologic deficit (no neurologic residua).<sup>20)</sup> Non-fatal ICH included ICH with major, minor or no neurologic deficit.<sup>21)</sup> Non-fatal gastrointestinal (GI) bleeding events included overt or occult GI tract bleeding. Non-fatal MI was defined MI events which was not related with death.

Over a period of 30 years using a societal perspective, quality-adjusted life expectancy, risk of adverse events, and net costs were quantified.

All costs were calculated in Korean won (KRW) and converted into US dollar (1 US dollar=1,000 KRW). Cost-effective therapies were selected using a willingness-to-pay threshold of \$30,000 per QALY gained.<sup>22)</sup> Model implementation, sensitivity analyses, and outcome calculations were performed using TreeAge Pro 2012 (TreeAge Inc, Williamstown, MA, USA).

### Probability and severity of adverse events

In our study, the probability parameters of NOACs and adverse events of warfarin were based on nation specific real-world data using HIRA registration data.



**Figure 1.** Schematic representation of Markov model shows that all patients start at 65 years of age with AF and then cycle between health states until death occurs or the 20-year time horizon is reached. Probabilities of these events depend on prescribed therapies. The length of each cycle is 1 year. Patients can die from stroke, hemorrhage, MI, or other co-morbidities. Decision node (square), chance nodes (circles) under the control of transition probabilities, and terminal nodes (triangles) are depicted. AF = atrial fibrillation; ECH = extracranial hemorrhage; M = Markov node; MI = myocardial infarction; RIND = reversible ischemic neurological deficit.

In the diagnosis of AF, HIRA data were used to calculate the CHA<sub>2</sub>D<sub>2</sub>-VASc scores of patients, and also, the ratio of low, intermediate, and high-risk was calculated.<sup>6)</sup> Probabilities of adverse events for warfarin were calculated from pooled data. If ischemic stroke, transient ischemic accident (TIA), ICH or MI were non-fatal, they were considered as post disease status. In contrast, if they were fatal, they were considered to death. Non-fatal GI bleeding was considered to as “healthy with AF.”

### Utilities

The baseline patient utility value was adjusted for age, AF, and OAC treatment.<sup>23)</sup> Subsequent disutilities for ischemic stroke, neurological events with residual symptom, MI, GI hemorrhage, and minor hemorrhage were estimated using pooled nationally representative Medical Expenditure Panel Survey data, as well as derived from published population-specific articles.<sup>23)</sup>

### Cost

We defined the healthy state is assumed to be transition in annually. The transient probability is determined by the probability of an independent health event occurring within 1 year. The probability of occurrence of each health event was estimated based on the data of the newly diagnosed AF patient from January 1, 2012 to December 31, 2014.

The cost was composed of single event cost, medication cost, maintenance cost. The cost of each event (GI bleeding, hemorrhage, and MI) was defined as hospitalization costs for each health events and it was calculated based on HIRA data. Annual costs of medication were defined as 365 times the price of daily medication price also based on HIRA. Post-event cost was defined as the total cost minus medication cost and event related cost.

Costs and QALYs were implemented in each cycle according to the health state of patients. According to the amount of time a person spent in the health state, the costs and QALYs accrued for each Markov state were weighted. Costs were calculated in US dollars and utility was based on QALY units. The utility value corresponding to each health condition was defined in the existing literature. The cost-effectiveness of each healthy state was compared through an ICER. The willing-to-pay ratio was set at 30,000 USD/QALY to reflect the GDP (US \$29,115 in 2017). The discount rate is set at 5% per annum, reflecting the annual inflation rate in Korea.

## RESULTS

Number of patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc scores 0, 1 and  $\geq 2$  were 56 (0.2%), 1,944 (6.3%) and 28,650 (93.5%), respectively. In patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc scores  $\geq 2$ , the incidence rate of ischemic stroke was 3.11% and 3.76% in warfarin and rivaroxaban groups, respectively. The incidence rate of ICH was 0.42% and 0.15% in warfarin and rivaroxaban, respectively. Moreover, the incidence rate of GI bleeding was 0.32% and 0.15% in warfarin and rivaroxaban, respectively.

Warfarin disutility was 0.03 and rivaroxaban disutility was 0.004.<sup>24)25)</sup> Disutility of major ischemic stroke or ICH, GI bleeding, and MI were 0.75, 0.85, and 0.84, respectively. Annual medication cost was \$23 for warfarin and \$847.9 for rivaroxaban. The cost of major ischemic stroke, TIA, MI, hemorrhagic stroke, and GI bleeding were \$2,318.68, \$2,361.62, \$2,337.87, \$2,666.39, and \$3,218.91, respectively (**Table 1**).

**Table 1.** Base-case model variables and ranges used in sensitivity analysis

Model parameter		Base-case value (raw data)	Base-case value (%/year)	Distribution	Reference
<b>Underlying condition (CVS)</b>					
0		56/30,650	0.18%	Dirichlet (Alpha)	HIRA
1		1,944/30,650	6.34%	Dirichlet (Alpha)	HIRA
≥2		28,650/30,650	93.48%	Dirichlet (Alpha)	HIRA
<b>Proportion of the events</b>					
<b>Treatment effectiveness (%/year)</b>					
<b>Ischemic stroke</b>					
Warfarin	CVS=0	0/174	0.00%	Normal	HIRA
	CVS=1	5/6,645	0.08%	Normal	HIRA
	CVS≥2	594/19,095	3.11%	Normal	HIRA
Rivaroxaban	CVS=0	0/0	0.00%	Normal	HIRA
	CVS=1	1/17	5.88%	Normal	HIRA
	CVS≥2	26/692	3.76%	Normal	HIRA
<b>TIA (minor stroke)</b>					
Warfarin	CVS=0	0/12	0.00%	Normal	HIRA
	CVS=1	10/2,029	0.49%	Normal	HIRA
	CVS≥2	186/19,095	0.97%	Normal	HIRA
Rivaroxaban	CVS=0	0/0	0.00%	Normal	HIRA
	CVS=1	0/17	0.00%	Normal	HIRA
	CVS≥2	4/692	0.58%	Normal	HIRA
<b>ICH</b>					
Warfarin	CVS=0	0/12	0.00%	Normal	HIRA
	CVS=1	3/788	0.38%	Normal	HIRA
	CVS≥2	81/19,095	0.42%	Normal	HIRA
Rivaroxaban	CVS=0	0/0	0.00%	Normal	HIRA
	CVS=1	0/17	0.00%	Normal	HIRA
	CVS≥2	1/692	0.15%	Normal	HIRA
<b>GI bleeding</b>					
Warfarin	CVS=0	0/12	0.00%	Normal	HIRA
	CVS=1	2/788	0.25%	Normal	HIRA
	CVS≥2	61/19,095	0.32%	Normal	HIRA
Rivaroxaban	CVS=0	0/0	0.00%	Normal	HIRA
	CVS=1	0/17	0.00%	Normal	HIRA
	CVS≥2	1/692	0.15%	Normal	HIRA
<b>MI</b>					
Warfarin	CVS=0	0/12	0.00%	Normal	HIRA
	CVS=1	4/788	0.51%	Normal	HIRA
	CVS≥2	304/19,095	1.59%	Normal	HIRA
Rivaroxaban	CVS=0	0/0	0.00%	Normal	HIRA
	CVS=1	0/17	0.00%	Normal	HIRA
	CVS≥2	1/692	0.15%	Normal	HIRA
<b>Fatality</b>					
Ischemic stroke		440/19,001	2.32%	Beta	HIRA
GI bleeding		7/2,058	0.34%	Beta	HIRA
MI		40/5,286	0.76%	Beta	HIRA
ICH		47/2,430	1.93%	Beta	HIRA
<b>Utility (QALYs)</b>					
<b>Event-free AF patients</b>					
Warfarin disutility		0.03	0.03	Gamma	Reference <sup>1,2</sup>
Rivaroxaban disutility		0.004	0.004	Gamma	Reference <sup>1,2</sup>
<b>Ischemic stroke or ICH</b>					
Minor		0.39	0.39	Beta (0.0625)	Reference <sup>1,2</sup>
Major		0.75	0.75	Beta (0.0325)	Reference <sup>1,2</sup>
GI bleeding (temporary state)		0.85	0.85	Beta (0.0708)	Reference <sup>1,2</sup>
MI		0.84	0.84	Beta (0.0700)	Reference <sup>1,2</sup>
<b>Cost (\$)</b>					
<b>Medication cost (yearly)</b>					
Warfarin		23	23	Gamma	HIRA
Rivaroxaban		847.9	847.9	Gamma	HIRA

(continued to the next page)


**Table 1.** (Continued) Base-case model variables and ranges used in sensitivity analysis

Model parameter	Base-case value (raw data)	Base-case value (%/year)	Distribution	Reference
Event related cost (per event)				
Major ischemic stroke	2,318.68	2,318.68	Gamma	HIRA
TIA	2,361.62	2,361.62	Gamma	HIRA
MI	2,337.87	2,337.87	Gamma	HIRA
Hemorrhagic stroke	2,666.39	2,666.39	Gamma	HIRA
GI bleeding	3,218.91	3,218.91	Gamma	HIRA

AF = atrial fibrillation; CVS = congestive heart failure, hypertension, age  $\geq 75$  (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65 to 74, female (CHA<sub>2</sub>DS<sub>2</sub>-VASc) score; GI = gastrointestinal; HIRA = Health Insurance Review & Assessment Service; ICH = intracranial hemorrhage; MI = myocardial infarction; QALYs = quality-adjusted life years; TIA = transient ischemic attack.

### Cost-effectiveness of rivaroxaban and warfarin

Under base-case hypothesis, patients who treated with adjusted-dose warfarin lived an average of 11.4±0.2 QALYs, and caused mean lifetime treatments costs of \$17,151. Those treated with rivaroxaban lived a mean of 11.8±0.2 QALYs, with an average lifetime cost of \$20,886 (**Table 2**). **Figure 2** shows the cost-effectiveness scatterplot of rivaroxaban and warfarin.



**Figure 2.** Cost-effectiveness scatterplot. QALY = quality-adjusted life-year.

**Table 2.** Descriptive statistics of cost and effectiveness for warfarin and rivaroxaban

Variables	Cost (\$)*		Effectiveness (QALYs)	
	Warfarin	Rivaroxaban	Warfarin	Rivaroxaban
Mean±SD	17,151±185	20,886±195	11.4±0.2	11.8±0.2
Median	17,151	20,885	11.4	11.8
Minimum	16,506	20,156	10.4	10.8
Maximum	17,834	21,663	12.1	12.5
Sum	171,505,530	208,855,207	114,276.8	118,124.5
Size	10,000	10,000	10,000	10,000
Variance	34,139	38,069	0.0	0.0
Variance/size	3	4	0.0	0.0
SQRT (variance/size)	2	2	0.0	0.0

SD = standard deviation; SQRT, square root; QALYs = quality-adjusted life-years.


\*All costs were calculated in Korean won and converted into US dollar (1 US dollar=1,000 KRW).

**Table 3.** Cost, benefits and incremental cost-effectiveness ratio for base-case analysis over a life-time

Strategy	Cost (\$)*	Incremental cost	QALY	ICER (\$/QALY)
<b>Total (n=20,604)</b>				
Warfarin (n=19,895)	17,151	Reference	11.43	Reference
Rivaroxaban (n=709)	20,886	3,735	11.81	9,707
<b>CHA<sub>2</sub>DS<sub>2</sub>-VASc score=1 (n=805)</b>				
Warfarin (n=788)	10,533	Reference	11.58	Reference
Rivaroxaban (n=17)	25,039	14,506	11.73	98,051
<b>CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥2 (n=28,650)</b>				
Warfarin (n=19,095)	17,612	Reference	11.42	Reference
Rivaroxaban (n=709)	20,617	3,005	11.82	7,536

CHA<sub>2</sub>DS<sub>2</sub>-VASc = congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65 to 74, female; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year.

\*All costs were calculated in Korean won and converted into US dollar (1 US dollar=1,000 KRW).



**Figure 3.** Changes in ICER estimates for rivaroxaban compared to warfarin with different time horizons. Employing a shorter time horizon (e.g., 1 year) results in a peak ICER of \$9,707 per QALY. Vertical dotted line demarcates the \$9,707 per QALY threshold.

ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year.

### Incremental cost-effectiveness ratio

Cost, benefits and ICER for base-case analysis over a life-time is presented in **Table 3**. While the ICER for rivaroxaban was \$9,707 per QALY in total AF patients, it was \$7,536 per QALY in those with high stroke risk (CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥2). **Figure 3** shows that rivaroxaban is more cost-effective with willingness-to-pay more than \$9,707.

## DISCUSSION

The cost-effectiveness analysis demonstrated that rivaroxaban may be a cost-effective alternative to warfarin in Korean patients with AF. Patients with rivaroxaban needed an additional cost of \$3,735, but gained an additional 0.4 QALYs over a lifetime, resulting in an ICER of \$9,707 per QALY. The probability of rivaroxaban was remaining cost-effective at willingness-to-pay thresholds of \$9,707 per QALY in Monte Carlo simulation. To our knowledge, this is the first study which demonstrate that rivaroxaban is cost-effective in Korean AF patients.



Current guidelines for stroke prevention published by the 2016 European Society of Cardiology and 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society recommend OAC, and NOAC as an alternative to warfarin for patients with high stroke risk factors (i.e., CHA<sub>2</sub>DS<sub>2</sub>-VASc score  $\geq 2$ ).<sup>17)</sup> Although the cost-effectiveness of NOAC had been identified in Korea, it was evaluated in many countries.

Dabigatran found a cost-effective alternative to warfarin in all economic models performed at a \$50,000–\$100,000 per QALY willingness-to-pay threshold. Dabigatran was reported to be a cost-effective alternative to warfarin in Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial (ICER of US \$45,372 per QALY),<sup>26)</sup> and from a Canadian (Canada \$10,440 per QALY) and United Kingdom health care perspective (€26,700 per QALY), respectively.<sup>27)28)</sup>

Markov model using a United States payer/Medicare perspective and a lifetime time horizon showed that the ICER for rivaroxaban was \$27,498 per QALY.<sup>29)</sup> Our Markov model demonstrated that the ICER for rivaroxaban was \$9,707 per QALY in total Korean AF patients. Interestingly, the cost-effectiveness was improved with \$7,536 per QALY in Korean AF patients with high stroke risk (CHA<sub>2</sub>DS<sub>2</sub>-VASc score  $\geq 2$ ). ICER of intermediate risk (CHA<sub>2</sub>DS<sub>2</sub>-VASc score=1) group was higher than that of high-risk group. This finding might be caused by small number of rivaroxaban group with intermediate risk (n=17) rather than low cost-effectiveness of rivaroxaban. In addition, ICER cannot be calculated in low risk group because there were none who was described rivaroxaban in this group

Interestingly, the ICER for rivaroxaban calculated in Korean AF was much lower than those reported in previous studies.<sup>28)29)</sup> The favorable ICER seen in our model reflects the decreased costs and increased QALYs resulting from relatively low price of NOAC in Korea and the avoidance of ICH with rivaroxaban compared to warfarin.

A recent meta-analysis reported that assuming that the UK National Health Service is willing to pay £20,000 for each year of perfect health (one QALY), all NOACs have a positive expected incremental net benefit compared with warfarin. Apixaban 5 mg twice daily has the highest expected incremental net benefit (£7533), followed by dabigatran 150 mg twice daily (£6,365), rivaroxaban 20 mg once daily (£5,279), and edoxaban 60 mg once daily (£5,212).<sup>30)</sup> Therefore, other NOACs which is not evaluated in this study may be cost-effective in Korean patients with AF.

There are several limitations to this study. First, in this study, the use of NOACs including rivaroxaban was extremely low compared with warfarin resulting in big difference of patient numbers between warfarin and NOACs. However, study number of patients with rivaroxaban might not affect the direction of the result. Small study number usually exaggerates incidence of events and worsen the treatment effectiveness of study drugs. Therefore, small study number could act as a bias that leads the result toward the null. Our result revealed that rivaroxaban was cost-effective. Moreover, based on Markov chain Monte Carlos methods, small study size can be somehow overcome by the number of iteration. We conducted 10,000 iterations for each cycle and it is enough to compensate sample size. However, further study with larger size is needed for the size of effect, because the effectiveness of rivaroxaban could be underestimated due to small study size. Second, health events were analyzed using Korean National Health Insurance Service (KNHIS) data for three years from January 2012 to December 2014 and this data will not fully reflect the efficacy and safety of the real

world. Considering that NOAC has been used in Korea since 2011 for the stroke prevention of nonvalvular AF patients, relatively early data might be included in this study. Third, as in similar models, we assumed any major bleeding would result in permanent discontinuation of rivaroxaban or warfarin and initiation of aspirin. This may not always be the case and would likely be based on individual patient factors.

In conclusion, the cost-effectiveness analysis demonstrated that rivaroxaban may be a cost-effective alternative to warfarin in Korean patients with AF. Patients with rivaroxaban needed an additional cost of \$3,735, but gained an additional 0.4 QALYs over a lifetime, resulting in an ICER of \$9,707 per QALY. The probability of rivaroxaban was remaining cost-effective at willingness-to-pay thresholds of \$9,707 per QALY in Monte Carlo simulation. To our knowledge, this is the first study which demonstrate that rivaroxaban is cost-effective in Korean AF patients.

## SUPPLEMENTARY MATERIAL

### Supplementary Table 1

Definitions and ICD-10 codes used for defining the comorbidities and clinical outcomes

[Click here to view](#)

## REFERENCES

1. Lee H, Kim TH, Baek YS, et al. The trends of atrial fibrillation-related hospital visit and cost, treatment pattern and mortality in Korea: 10-year nationwide sample cohort data. *Korean Circ J* 2017;47:56-64.  
[PUBMED](#) | [CROSSREF](#)
2. Kim TH, Yang PS, Uhm JS, et al. CHA<sub>2</sub>DS<sub>2</sub>-VASc score (congestive heart failure, hypertension, age ≥75 [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65–74, female) for stroke in Asian patients with atrial fibrillation: a Korean nationwide sample cohort study. *Stroke* 2017;48:1524-30.  
[PUBMED](#) | [CROSSREF](#)
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med* 2007;146:857-67.  
[PUBMED](#) | [CROSSREF](#)
4. Decker C, Garavalia L, Garavalia B, et al. Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians. *J Multidiscip Healthc* 2012;5:129-35.  
[PUBMED](#) | [CROSSREF](#)
5. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361:1139-51.  
[PUBMED](#) | [CROSSREF](#)
6. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011;365:883-91.  
[PUBMED](#) | [CROSSREF](#)
7. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011;365:981-92.  
[PUBMED](#) | [CROSSREF](#)
8. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2013;369:2093-104.  
[PUBMED](#) | [CROSSREF](#)
9. Nelson WW, Song X, Coleman CI, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. *Curr Med Res Opin* 2014;30:2461-9.  
[PUBMED](#) | [CROSSREF](#)

10. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *Eur Heart J* 2012;33:2719-47.  
[PUBMED](#) | [CROSSREF](#)
11. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol* 2014;64:e1-76.  
[PUBMED](#) | [CROSSREF](#)
12. Kim D, Yang PS, Jang E, et al. 10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. *Am Heart J* 2018;202:20-6.  
[PUBMED](#) | [CROSSREF](#)
13. Kim D, Yang PS, Jang E, et al. Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015. *Heart* 2018;heartjnl-2017-312930.  
[PUBMED](#) | [CROSSREF](#)
14. Baek YS, Yang PS, Kim TH, et al. Associations of abdominal obesity and new-onset atrial fibrillation in the general population. *J Am Heart Assoc* 2017;6:e004705.  
[PUBMED](#) | [CROSSREF](#)
15. Lee HY, Yang PS, Kim TH, et al. Atrial fibrillation and the risk of myocardial infarction: a nation-wide propensity-matched study. *Sci Rep* 2017;7:12716.  
[PUBMED](#) | [CROSSREF](#)
16. Ades AE, Cliffe S. Markov chain Monte Carlo estimation of a multiparameter decision model: consistency of evidence and the accurate assessment of uncertainty. *Med Decis Making* 2002;22:359-71.  
[PUBMED](#) | [CROSSREF](#)
17. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016;37:2893-962.  
[PUBMED](#) | [CROSSREF](#)
18. Korean Statistical Information Service (KOSIS). Korean life expectation. 2016.
19. Kim TH, Yang PS, Yu HT, et al. Age threshold for ischemic stroke risk in atrial fibrillation: cohort data covering the entire Korean population. *Stroke* 2018;39:ehy565.P2904.
20. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. *JAMA* 2005;293:699-706.  
[PUBMED](#) | [CROSSREF](#)
21. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. *Ann Intern Med* 1994;120:897-902.  
[PUBMED](#) | [CROSSREF](#)
22. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence. *Health Aff (Millwood)* 2000;19:92-109.  
[PUBMED](#) | [CROSSREF](#)
23. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. *Med Decis Making* 2006;26:410-20.  
[PUBMED](#) | [CROSSREF](#)
24. Lanitis T, Kongnakorn T, Jacobson L, De Geer A. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation. *Thromb Res* 2014;134:278-87.  
[PUBMED](#) | [CROSSREF](#)
25. Magnuson EA, Vilain K, Wang K, et al. Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. *Am Heart J* 2015;170:1140-50.  
[PUBMED](#) | [CROSSREF](#)
26. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. *Ann Intern Med* 2011;154:1-11.  
[PUBMED](#) | [CROSSREF](#)
27. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. *Thromb Haemost* 2011;105:908-19.  
[PUBMED](#) | [CROSSREF](#)
28. Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. *BMJ* 2011;343:d6333.  
[PUBMED](#) | [CROSSREF](#)

29. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. *Am J Cardiol* 2012;110:845-51.  
[PUBMED](#) | [CROSSREF](#)
30. López-López JA, Sterne JA, Thom HH, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. *BMJ* 2017;359:j5058.  
[PUBMED](#) | [CROSSREF](#)